Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients
with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help
reduce the number of laser treatments that might be needed to control the tumor.